Search

New MSK research supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN-mutated prostate cancers; provides new understanding of B cell lymphomas that could lead to new treatments; examines using ChatGPT to help capture patient-reported outcomes; and developed the first customizable, scalable model for palliative care training for emergency departments.

… Thursday, February 13, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) supported the approval of a new treatment for ER-positive, HER2-negative advanced breast cancer; suggests a new strategy for overcoming resistance to Akt inhibitors in patients with PTEN -mutated prostate cancers

Research by a team at Memorial Sloan Kettering Cancer Center has found important new insights into colorectal cancer in Nigeria that have significant implications for treating the disease in West Africa. This research also expands awareness of how different population groups may require different approaches in the diagnosis and treatment of cancer.

… Wednesday, November 24, 2021 Colorectal cancer is common — and deadly — around the world.   But too often, major population groups are not represented in colorectal cancer research, which focuses mainly on patients in America and Western Europe.   A team of researchers from Memorial Sloan Kettering Cancer

The Patient and Family Advisory Council for Quality (PFACQ) marks five years of ensuring the patient and family perspective is included in everything MSK does.

… Wednesday, January 1, 2020 In 2014, Kate Niehaus, a former patient active in volunteer work for Memorial Sloan Kettering, was approached by Kent Sepkowitz, an infectious disease specialist and Deputy Physician-in-Chief for Quality and Safety, with a proposal to make MSK’s outstanding cancer care even

Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries molecular changes called NPM1 mutations and KMT2A translocations.

… Wednesday, October 29, 2025 On October 24, 2025, the U.S. Food and Drug Administration (FDA)  approved revumenib (Revuforj ® ) for patients 1-year-old and older who have leukemia that has come back after treatment and whose cancer carries a molecular change called an NPM1 mutation. In November 2024,

Mutations that drive cancer growth also make a cell more noticeable to the immune system.

… Wednesday, May 11, 2022 Many cancers contain similar genetic “hotspots” — areas of DNA that are likely to be mutated. For example, more than 50% of cancers contain a mutation in a gene called TP53 , often within a narrow DNA range. Researchers know that hotspots can contribute to cancer development and

Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to Newsweek’s World’s Best Specialized Hospitals 2026 list.

… Thursday, October 30, 2025 Memorial Sloan Kettering Cancer Center (MSK) is ranked the number one hospital in the world for oncology according to  Newsweek’s   World’s Best Specialized Hospitals 2026 list. “Earning the distinction as the world’s top hospital for oncology is a profound honor that reflects

Memorial Sloan Kettering’s Vivian Strong, MD, FACS, addressed peers from around the world in May 2025 at the 16th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global Fight for Innovation, the U.S. Perspective,” as the meeting’s Jin Pok Kim Lecturer.

… Thursday, May 8, 2025 Memorial Sloan Kettering’s  Vivian Strong, MD, FACS , addressed peers from around the world in May 2025 at the 16 th Annual International Gastric Cancer Congress. Dr. Strong, a surgeon and MSK’s Iris Cantor Chair in Honor of Dr. Sidney Winawer, presented, “Gastric Cancer: A Global

The first large study of its kind has found that having a healthy microbiota before starting the process of a bone marrow transplant using a patient’s own cells (autologous) leads to fewer complications after the procedure.

… Thursday, March 18, 2021 A patient’s health after a stem cell or bone marrow transplant (BMT) can depend on the bacteria in their gut. The trillions of microorganisms living there are also known as the microbiota. They can be damaged or wiped out by cancer treatments, leaving patients with severe intestinal

In a study published in the New England Journal of Medicine (NEJM), an MSK team report that they have found what enables cancer cells to become resistant to the experimental drug pirtobrutinib.

… Thursday, February 24, 2022 Since the first targeted therapies for blood cancer were developed more than 20 years ago, doctors and scientists have observed that many patients who respond well to these drugs initially end up developing resistance to them over time. There is an assumption among scientists

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.

… Thursday, June 6, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Andrea Cercek Named to the Inaugural 2024 TIME100 Health List Andrea Cercek Named to the Inaugural 2024 TIME100 Health List Andrea Cercek, MD , gastrointestinal oncologist, section